Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K.

Eur J Nucl Med Mol Imaging. 2019 Aug 22. doi: 10.1007/s00259-019-04485-3. [Epub ahead of print]

PMID:
31440799
2.

Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C.

AJR Am J Roentgenol. 2019 Aug;213(2):275-285. doi: 10.2214/AJR.18.20845. Epub 2019 Apr 17.

PMID:
30995089
3.

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S.

Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.

PMID:
29752180
4.

Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.

von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16. Review.

5.

[177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer].

Boegemann M, Schrader AJ, Rahbar K.

Urologe A. 2017 Nov;56(11):1440-1444. doi: 10.1007/s00120-017-0510-5. Review. German.

PMID:
28986618
6.

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ.

J Nucl Med. 2016 Jul;57(7):1006-13. doi: 10.2967/jnumed.115.168443. Epub 2016 Jan 21.

7.

Prostate-specific membrane antigen theranostics: therapy with lutetium-177.

Ferdinandus J, Violet J, Sandhu S, Hofman MS.

Curr Opin Urol. 2018 Mar;28(2):197-204. doi: 10.1097/MOU.0000000000000486. Review.

PMID:
29278583
8.

[Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].

Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, Dietlein M, Drzezga A, Fabry U, Feldmann G, Heidenreich A, Heinzel A, Herrmann K, Heyll A, Höhling C, Kreuzer C, Laufer D, Mengel R, Mottaghy FM, Müller HW, Müller SC, Ost E, Rahbar K, Reifenhäuser W, Schäfers M, Schlenkhoff C, Schmidt M, Schmidt-Wolf I, Wildenhain C, Zimmer B, Essler M.

Urologe A. 2018 Jun;57(6):709-713. doi: 10.1007/s00120-018-0642-2. German.

PMID:
29671080
9.

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.

Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M.

Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22.

PMID:
30473431
10.

PSMA Theranostics: Current Status and Future Directions.

Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H.

Mol Imaging. 2018 Jan-Dec;17:1536012118776068. doi: 10.1177/1536012118776068. Review.

11.

[PSMA-targeted radioligand therapy in prostate cancer].

Heck MM, Retz M, Tauber R, Knorr K, Kratochwil C, Eiber M.

Urologe A. 2017 Jan;56(1):32-39. doi: 10.1007/s00120-016-0274-3. Review. German.

PMID:
27885457
12.

Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51. doi: 10.1007/s00259-015-3174-7. Epub 2015 Aug 29.

PMID:
26318602
13.

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.

Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, Ravi Kumar A, Murphy DG, Williams SG, Hicks RJ, Hofman MS.

Eur Urol Oncol. 2018 Dec 13. pii: S2588-9311(18)30205-0. doi: 10.1016/j.euo.2018.11.007. [Epub ahead of print]

PMID:
31412006
14.

Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, Gaertner FC, Essler M, Ahmadzadehfar H.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073-1080. doi: 10.1007/s00259-018-4222-x. Epub 2018 Nov 24.

PMID:
30474706
15.

177Lu-PSMA Radioligand Therapy for Prostate Cancer.

Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M.

J Nucl Med. 2017 Aug;58(8):1196-1200. doi: 10.2967/jnumed.117.191023. Epub 2017 Jun 29. Review. Erratum in: J Nucl Med. 2018 Feb;59(2):346.

16.

Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.

Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):243-246. doi: 10.1007/s00259-017-3877-z. Epub 2017 Nov 13.

PMID:
29134280
17.

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.

Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J.

J Med Radiat Sci. 2017 Mar;64(1):52-60. doi: 10.1002/jmrs.227. Review.

18.

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.

Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, Wei X, Schlenkhoff C, Hauser S, Essler M.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454. doi: 10.1007/s00259-017-3716-2. Epub 2017 May 9.

PMID:
28488028
19.

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ.

J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20.

20.

Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.

Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, Epstein R, Blanksby A, Horvath L, Guminski A, Mahon K, Gedye C, Yin C, Stricker P, Joshua AM.

Clin Genitourin Cancer. 2019 Feb;17(1):15-22. doi: 10.1016/j.clgc.2018.09.014. Epub 2018 Sep 27.

PMID:
30425003

Supplemental Content

Support Center